AstraZeneca Q4 Earnings Beat, Sales Hurt By COVID Jab

Core earnings of $1.38 per share declined 17% year over year on a reported basis and 5% at constant exchange rates (CER).
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.